Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Axsome Therapeutics (AXSM) Finished Goods (2022 - 2025)

Axsome Therapeutics' Finished Goods history spans 4 years, with the latest figure at $11.3 million for Q4 2025.

  • For Q4 2025, Finished Goods rose 25.53% year-over-year to $11.3 million; the TTM value through Dec 2025 reached $11.3 million, up 25.53%, while the annual FY2025 figure was $11.3 million, 25.53% up from the prior year.
  • Finished Goods for Q4 2025 was $11.3 million at Axsome Therapeutics, up from $10.3 million in the prior quarter.
  • Across five years, Finished Goods topped out at $11.3 million in Q4 2025 and bottomed at $1.6 million in Q4 2022.
  • The 4-year median for Finished Goods is $8.9 million (2024), against an average of $8.1 million.
  • The largest annual shift saw Finished Goods soared 506.48% in 2023 before it dropped 12.0% in 2025.
  • A 4-year view of Finished Goods shows it stood at $1.6 million in 2022, then skyrocketed by 506.48% to $9.6 million in 2023, then decreased by 6.81% to $9.0 million in 2024, then increased by 25.53% to $11.3 million in 2025.
  • Per Business Quant, the three most recent readings for AXSM's Finished Goods are $11.3 million (Q4 2025), $10.3 million (Q3 2025), and $9.5 million (Q2 2025).